Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies

(2015) T. R. W. Tipton et al.   BLOOD

THU0509 Longer Duration of B Cell Depletion in Patients with Systemic Lupus Erythematosus is Associated with A Better Outcome

(2014) V. Rodríguez-García et al.   ANNALS OF THE RHEUMATIC DISEASES

Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)

(2014) Chern Siang Lee et al.   BRITISH JOURNAL OF HAEMATOLOGY

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study

(2013) Luca Quartuccio et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibitory Fc RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

(2013) A. T. Vaughan et al.   BLOOD

Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus

(2013) V. Reddy et al.   RHEUMATOLOGY

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

(2013) Daniel J. Wallace et al.   RHEUMATOLOGY

B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design

(2013) Venkat Reddy et al.   ARTHRITIS RESEARCH & THERAPY

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

(2012) P. P. Tak et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

(2011) P. C. Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

B cell biomarkers of rituximab responses in systemic lupus erythematosus

(2011) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

(2011) S. H. Lim et al.   BLOOD

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

(2011) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion

(2010) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody

(2010) R. Herbst et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The role of defective clearance of apoptotic cells in systemic autoimmunity

(2010) Luis E. Muñoz et al.   Nature Reviews Rheumatology

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases

(2009) M Ramos-Casals et al.   LUPUS

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

(2008) D Albert et al.   ANNALS OF THE RHEUMATIC DISEASES

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

(2008) Shouvik Dass et al.   ARTHRITIS AND RHEUMATISM

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

(2008) S. A. Beers et al.   BLOOD